M&A Deal Summary

Amgen Acquires Otezla

On August 26, 2019, Amgen acquired life science company Otezla from Celgene for 13.4B USD

Acquisition Highlights
  • This is Amgen’s 15th transaction in the Life Science sector.
  • This is Amgen’s 3rd largest (disclosed) transaction.
  • This is Amgen’s 12th transaction in the United States.

M&A Deal Summary
Date 2019-08-26
Target Otezla
Sector Life Science
Buyer(s) Amgen
Sellers(s) Celgene
Deal Type Divestiture
Deal Value 13.4B USD

Target

Otezla

United States
Otezla is a treatment in the post-topical, pre-biologic segment in its approved indications. Otezla is currently approved for three indications in the U.S.—the treatment of patients with moderate-to-severe plaque psoriasis who are candidates for phototherapy or systemic therapy; adult patients with active psoriatic arthritis; and adult patients with oral ulcers associated with Behçet's Disease.

Search 200,500 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Amgen

Thousand Oaks, California, United States
Category Company
Founded 1980
Sector Life Science
Employees26,700
Revenue 28.2B USD (2023)
DESCRIPTION
Entrance to Amgen's corporate campus in Thousand Oaks, California.
Entrance to Amgen's corporate campus in Thousand Oaks, California.

Amgen is a drug development company focused on discovering, developing, manufacturing and delivering human therapeutics. Amgen uses tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology. Amgen focuses on areas of high unmet medical need and leverages its biologics manufacturing expertise to strive for solutions that improve health outcomes and people's lives. Amgen was founded in 1980 and is based in Thousand Oaks, California.

DEAL STATS #
Overall 16 of 21
Sector (Life Science) 15 of 20
Type (Divestiture) 1 of 1
Country (United States) 12 of 16
Year (2019) 1 of 1
Size (of disclosed) 3 of 20
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2015-09-16 Dezima Pharma BV

Naarden, Netherlands

Dezima Pharma BV is a biotechnology company developing innovative drugs to treat dyslipidemic patients suffering from cardiovascular disease (CVD).

Buy -
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2021-03-04 Five Prime Therapeutics

South San Francisco, California, United States

Five Prime Therapeutics, Inc. is a pre-clinical stage biotech company discovering innovative protein and antibody therapeutics. By tackling the tough scientific questions and untapped pathways, we aim to offer new hope by developing novel, breakthrough therapies that have potential to alter the course of disease in cancers with few treatment options. Five Prime Therapeutics was founded in 2001 and is based in South San Francisco, California.

Buy $1.9B

Seller(S) 1

SELLER

Celgene

Summit, New Jersey, United States
Category Company
Founded 1980
Sector Life Science
Employees6,971
Revenue 13.0B USD (2017)
DESCRIPTION

Celgene Corp. is an integrated biopharmaceutical company engaged primarily in the discovery, development and commercialization of innovative therapies for the treatment of cancer and inflammatory diseases through gene and protein regulation. Celgene Corp. was established in 1980 and is headquartered in Summit, New Jersey.

DEAL STATS #
Overall 2 of 3
Sector (Life Science) 1 of 2
Type (Divestiture) 1 of 1
Country (United States) 1 of 2
Year (2019) 1 of 1
Size (of disclosed) 1 of 2
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2018-01-22 Juno Therapeutics

Seattle, Washington, United States

Juno Therapeutics, Inc. is a biopharmaceutical company focused on revolutionizing medicine by re-engaging the body's immune system to treat cancer. Juno Therapeutics was founded in 2013 and is based in Seattle, Washington.

Buy $9.0B
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2020-01-07 PharmAkea

San Diego, California, United States

PharmAkea is a biopharmaceutical company and is a developer of high-quality, small molecule drug candidates against protein targets involved in fibroproliferative diseases. PharmAkea was founded in 2012 and is based in San Diego, California.

Sell -
Mergr

Product

Company

Legal